Next-GenerationPediatric Cancer Models: Patient-Matched Orthotopic Xenografts, 3D Organoids, 2D Cultures, and Cell Lines for Identification of Therapeutic Vulnerabilities in Pediatric Solid Tumors [scRNAseq]
Single-cell RNA-seq · human · 59 samples
- What it is
- Single-cell RNA-seqGene activity measured in thousands of individual cells, so cell types can be told apart.
- Organism
- Homo sapiens (human)
- Samples
- 59 samples: 58 distinct titles, 1 of them repeatedGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE319124_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Single-cell studies usually ship their counts as 10x files (matrix.mtx, barcodes.tsv, features.tsv), an .h5 file, or an .rds / .h5ad object that Seurat or Scanpy can open. Look for those among the supplementary files.
Also filed as BioProject PRJNA1422141 and SRA study SRP676295. Searching any of these in the dataset finder brings you back here.
How we read this: Read from 59 sample titles: 58 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9511111 SJRHB010928_C1_DYE0282
- GSM9511112 SJEWS063826_X1_DYE1472
- GSM9511113 SJRHB013758_C4_DYE1672
- GSM9511114 SJRHB013758_C2 Rep 1_DYE1676
- GSM9511115 SJRHB000026_C5_DYE1680
- GSM9511116 SJRHB010928_C3_DYE1682
- GSM9511117 SJOS030605_X2_DYE1707
- GSM9511118 SJRHB013759_C10_DYE2108
- GSM9511119 SJOS030605_C3_DYE2109
- GSM9511120 SJEWS056156_C3_DYE2111
- GSM9511121 SJNBL046_X_DYE2340
- GSM9511122 SJRHB000026_X1_DYE2379
- GSM9511123 SJRHB010928_X1_DYE2511
- GSM9511124 SJNBL031239_D1_DYE2515
- GSM9511125 SJNBL012407_C3_DYE2545
- GSM9511126 SJNBL046148_C3_DYE2546
- GSM9511127 SJEWS030393_C3_DYE2547
- GSM9511128 SJEWS063826_C3_DYE2548
- GSM9511129 SJRHB013758_C6_DYE2549
- GSM9511130 SJNBL031239_C5_DYE2550
- GSM9511131 SJNBL030721_C14_DYE2551
- GSM9511132 SJNBL013762_C3_DYE2552
- GSM9511133 SJEWS056156_C4_DYE2554
- GSM9511134 SJRHB000026_C6_DYE2555
- GSM9511135 SJOS030605_C4_DYE2556
- GSM9511136 SJEWS063826_C4_DYE2557
- GSM9511137 SJRHB013758_C7_DYE2558
- GSM9511138 SJNBL031239_X1_DYE2577
- GSM9511139 SJRHB010927_X1_DYE2580
- GSM9511140 SJRHB013758_X2_DYE2618
- GSM9511141 SJRHB010928_R1_DYE2661
- GSM9511142 SJRHB013759_A1_DYE2835
- GSM9511143 SJRHB013758_D2_DYE2837
- GSM9511144 SJRHB013758_D1_DYE2839
- GSM9511145 SJRHB000026_R2_DYE2840
- GSM9511146 SJEWS063826_D1_DYE3065
- GSM9511147 SJNBL012407_D1_DYE3066
- GSM9511148 SJNBL030721_D1_DYE3128
- GSM9511149 SJNBL030721_D5_DYE3129
- GSM9511150 SJNBL063821_X1_DYE4555
+ 19 more — browse all 59 samples with per-sample file links →
- GSE275870 Expression profiling of primary and metastatic oral squamous cell carcinoma identifies progression-associated transcriptome changes and therapeutic vulnerabilities 108 samples shares vulnerabilities, therapeutic
- GSE294016 A macrophage-predominant, immunosuppressive immune microenvironment and subtype-specific therapeutic vulnerabilities in advanced salivary gland cancer [bulk RNA-seq] 95 samples shares vulnerabilities, therapeutic
- GSE294017 A macrophage-predominant, immunosuppressive immune microenvironment and subtype-specific therapeutic vulnerabilities in advanced salivary gland cancer [Single nuclei RNAseq] 16 samples shares vulnerabilities, therapeutic
- GSE269942 YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities 12 samples shares vulnerabilities, therapeutic
- GSE285857 Mutant KRAS-Driven Selective mRNA Translation Reveals Mechanisms and Therapeutic Vulnerabilities in Cancer 48 samples shares vulnerabilities, therapeutic
- GSE309595 Longitudinal Analysis of Multiple Myeloma: Therapeutic Response and Immune Microenvironment Dynamics in the Context of Tumor Heterogeneity [scRNA-seq] 270 samples shares therapeutic
- GSE215274 Identification of Whole Blood Gene Expression Signature to Predict the Therapeutic Effect of Nintedanib in Idiopathic Pulmonary Fibrosis 177 samples shares therapeutic
- GSE268177 Modulating alternative splicing of MECP2: A potential therapeutic strategy for Rett syndrome 93 samples shares therapeutic
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.